View profile

FarmaKology-Viagra could be used to treat Alzheimer’s disease

Revue
 
 

FarmaKology

January 4 · Issue #91 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+13K Subscribers )!

Novo Banking
Novo Banking
Today's Company
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries across the world is accomplishing. We redefine what it means to be a big company in today’s world.
News
Immix Biopharma, Inc. , a biopharmaceutical company pioneering Tissue-Specific Therapeutics TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial.
Oncoheroes Biosciences, Inc., and Allarity Therapeutics, Inc have signed a worldwide, exclusive pediatric licensing agreement for dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, both being developed by Allarity.
Spero Therapeutics, Inc., today announced that the U.S. Food and Drug Administration  has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms. Tebipenem HBr has been granted Qualified Infectious Disease Product , Fast Track, and Priority Review designations for these cUTI indications. 
Ascletis Pharma Inc. today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The Company’s COVID-19 pipeline currently includes ritonavir oral tablet (100 mg), an authorized product, ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor.
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate, OV350. The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.
Spend $1 Today, Save up to $2k on Your Next Vacay with Dollar Flight Club.
Research & Study
Podcast
Stream Episode 113 - Illinois' Drug Repository Program with Dr. Elizabeth Lindquist by Political Pharmacist | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar
Video
Omicron is displacing delta science
Anycart
Anycart
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue